中國再生醫學(08158.HK)再出售醫療產品產業基金權益 料獲利約167萬元
中國再生醫學(08158.HK)公布,全資附屬CRML早前曾投資皮膚護理及醫療產品行業產業基金Haitong International ZhongHua Finance Acquisition Fund I,L.P.,注資總額3,500萬美元。CRML早前計劃向投資者熊千根出售於該基金投資的15%權益,作價580萬美元。
集團指,CRML計劃進一步向投資者熊千根出售基金權益,代價為3,290萬美元,佔轉讓基金注資面值的85%。
根據代價減交易成本及出售權益的賬面值,出售事項將會錄得獲利約167萬港元。出售事項的所得款項現金淨額將約為2.25億港元。所得款項現金淨額用作以下用途約2,640萬港元用於按等額基準進一步抵銷CRML及/或集團欠付及結欠熊先生的款項;約1,950萬港元用於償還應付貿易賬款;)約5,050萬港元用於償還應計費用及其他應付賬項;約6,250萬港元用於支付員工成本;約550萬港元用於支付租金及收費;約1,170萬港元用於支付水電費及其他開支;約1,550萬港元用於支付專業費用及公司開支;及約3,320萬港元用於支付廣告、營銷及推廣開支。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.